Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More
Close
Dismiss

Codman Neuro buys Irish medical devices maker Neuravi

Johnson & Johnson’s (J&J) subsidiary Codman Neuro has acquired Irish medical devices maker Neuravi for an undisclosed sum.

Codman Neuro’s affiliate DePuy Ireland acquired Neuravi, which is engaged in the development and marketing of advanced medical devices for neurointerventional therapy that are used for acute ischemic stroke patients.

Last December, Codman Neuro also acquired US-based Pulsar Vascular, which provides breakthrough platform technology for the neurovascular treatment of complex aneurysms.

Both acquisitions will enable Codman Neuro to provide a comprehensive portfolio of products for hemorrhagic and ischemic stroke.

Neuravi has developed EmboTrap revascularization platform for the treatment of different clots that cause acute ischemic stroke.

EmboTrap device has been developed to restore blood flow to the brain by repairing a clot with its advanced dual-layer stent-like structure.

EmboTrap and EmboTrap II revascularization devices are currently available for the treatment of patients in Europe.

They are available in the US for investigational use only under the ARISE II clinical trial, which could be used to secure approval from the US Food and Drug Administration (FDA).

Johnson & Johnson Medical Devices Cardiovascular & Specialty Solutions company group chairman Shlomi Nachman said: "Rapid restoration of flow is of utmost importance when treating stroke patients.

"The EmboTrap platform was designed to address this critical need and we are excited to combine Neuravi's expertise in clot research with Codman Neuro's global resources to accelerate innovation in acute ischemic stroke treatment."

As per the European Journal of Neurology, the number of stroke events in Europe is expected to increase from 1.1 million in 2000 to 1.5 million per year by 2025.


Image: Neuravi’s EmboTrap II revascularization device. Photo: courtesy of PRNewsfoto / Codman Neuro.